Clinical trial
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail…
NCT00250042 · New Mexico Cancer Research Alliance, Other · Completed
Key facts
| NCT number | NCT00250042 |
|---|---|
| Title | A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec |
| Official title | A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail to Achieve a Complete Response to Initial Gleevec Treatment |
| Lead sponsor | New Mexico Cancer Research Alliance, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Other, Cancer |
| Intervention type | Drug |
| Interventions | Gleevec and Arsenic Trioxide |
| Enrollment | 6 |
| Start date | Apr 1, 2004 |
| Primary completion | Apr 1, 2005 |
| Completion | Mar 1, 2006 |
| First posted | Nov 7, 2005 |
| Last update posted | Sep 20, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: